IrsiCaixa researchers published a new study showing that a new model improves the development of human immune cells involved in HIV persistence, detecting more HIV-associated signals in tissues than conventional models.

IrsiCaixa is a leading research institute in infections and immunity, jointly driven by the "la Caixa" Foundation and the Department of Health of the Government of Catalonia. Established in 1995 as a private non-profit foundation, with the primary goal of finding a solution to the then-devastating HIV/AIDS pandemic, IrsiCaixa brings together extensive knowledge in the field of infectious diseases and the immune system. While maintaining a strong commitment to eradicating HIV, more than 100 dedicated researchers explore other viral, bacterial, and fungal infections with significant clinical impact, such as COVID-19, syphilis, and Ebola, as well as diseases caused by respiratory syncytial virus and multidrug-resistant bacteria. IrsiCaixa leverages its extensive knowledge in immunology and vaccines to combat a broad spectrum of diseases and to reduce the impact of infections. Additionally, its scientific trajectory has led it to engage in other cross-cutting disciplines, such as understanding the role of microorganisms and the resulting immunological disorders to address medical challenges like cancer, Alzheimer's, aging, and the microbiome.